CD8A and Thrombocytopenia: Patients that are at risk of developing CRS are patients with high disease burden, an older age at the time of infusion, higher-intensity lymphodepleting regimen, utilization of fludarabine and cyclophosphamide during lymphodepleting chemotherapy, higher infused CAR T-cell doses, use of unselected bulk CD8+ T cells, high levels of CTL019+ CD8 and CD3 cells, the presence of inflammatory markers including a higher peak of C-reactive protein, and severe thrombocytopenia [25,27,33,34] (Table 7).